Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK
(2023)
Journal Article
Walsh, T. S., Aitken, L. M., McKenzie, C. A., Boyd, J., Macdonald, A., Giddings, A., Hope, D., Norrie, J., Weir, C., Parker, R. A., Lone, N. I., Emerson, L., Kydonaki, K., Creagh-Brown, B., Morris, S., McAuley, D. F., Dark, P., Wise, M. P., Gordon, A. C., Perkins, G., …Page, V. J. (2023). Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK. BMJ Open, 13(12), Article e078645. https://doi.org/10.1136/bmjopen-2023-078645
Introduction: Almost all patients receiving mechanical ventilation (MV) in intensive care units (ICUs) require analgesia and sedation. The most widely used sedative drug is propofol, but there is uncertainty whether alpha2-agonists are superior. The... Read More about Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK.